Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Atypical age-related cortical thinning in episodic migraine
Chong, Catherine D. , Schlaggar, Bradley L. , Schwedt, Todd J. , Dodick, David W. , Chong, Catherine D

Cephalalgia | April 29, 2014 | Volume: 34 | Issue: 14 | Pages: 1115-1124

10.1177/0333102414531157 | PMID 24781111 Get It

Background Prior studies demonstrate reduced cortical thickness and volume in migraineurs. However, the effect of age on cortical thickness has not been assessed in migraineurs. In this study we investigated whether the process of aging on cortical thickness affects migraineurs differently compared to age-matched healthy controls, i.e. whether aging exacerbates cortical thinning in migraineurs. Methods Cortical thickness was estimated using a general linear model vertex-by-vertex approach for 32 healthy controls (mean age = 35.3 years; SD = 11.6) and 27 episodic migraine patients (mean age = 33.6 years; SD = 12.3). Results were modeled using a main effect analysis to estimate the effect of age on cortical thickness for each group separately, and an age-by-group analysis to estimate differences in age-related cortical thinning between migraine patients and normal controls. Results Although migraineurs and normal controls both have expected age-related thinning in many regions along the cortical mantle, migraineurs have age-related thinning of regions that do not thin in healthy controls, including: bilateral postcentral, right fusiform, and right temporal pole areas. Cortical thinning of these regions is more prominent with advancing age. Conclusion Results suggest that migraine is associated with atypical cortical aging, suggesting that the migraine disease process interacts with aging to affect cortical integrity.
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study
Chee, Cheng E. , Ashrani, Aneel A. , Marks, Randolph S., Petterson, Tanya M. , Bailey, Kent R. , Melton, L. Joseph, Heit, John A.

Blood | April 29, 2014 | Volume: 123 | Issue: 25 | Pages: 3972-3978

10.1182/blood-2014-01-549733 | PMID 24782507 Get It

Key Points VTE recurrence risk in patients with cancer can be stratified by cancer type, stage, stage progression, and presence of leg paresis. Patients with cancer at high VTE recurrence risk should be considered for secondary prophylaxis.
Abiraterone Acetate to Lower Androgens in Women With Classic 21-Hydroxylase Deficiency
Auchus, Richard J. , Buschur, Elizabeth , Chang, Alice Y. , Hammer, Gary D. , Ramm, Carole A., Madrigal, David, Gonzalez, Martha, Xu, Xu Steven , Smit, Johan W., Jiao, James, Yu, Margaret K. , Wang, George C.

The Journal of Clinical Endocrinology & Metabolism | April 29, 2014 | Volume: 99 | Issue: 8 | Pages: 2763-2770

10.1210/jc.2014-1258 | PMID 24780050 Get It

An Independent Study of a Gene Expression Classifier (Afirma) in the Evaluation of Cytologically Indeterminate Thyroid Nodules
McIver, Bryan, Castro, M. Regina , Bernet, Victor , Smallridge, Robert C., Henry, Michael , Kosok, Laura, Morris, John C. , Reddi, Honey V.

The Journal of Clinical Endocrinology & Metabolism | April 29, 2014 | Volume: 99 | Issue: 11 | Pages: 4069-4077

10.1210/jc.2013-3584 | PMID 24780044 Get It

Context: Molecular markers hold the promise of improved diagnostic yield in thyroid fine-needle biopsy. The Afirma gene expression classifier (GEC), available commercially, reports a negative predictive value of 94% in the diagnosis of benign nodules after indeterminate cytology. However, there are currently no independent studies of the performance of this assay. Objective: The aim was to assess the performance of the Afirma GEC in an academic medical center. Design: Samples for the GEC were collected according to the manufacturer's recommended protocol from patients undergoing thyroid fine-needle aspiration. We requested GEC analysis on nodules reported cytologically as follicular neoplasm or atypia or follicular lesion of undetermined significance from patients willing to defer surgery. Patients: All patients undergoing thyroid fine-needle aspiration during the study period, whose cytology was reported as follicular neoplasm or atypia of undetermined significance/follicular lesion of undetermined significance, were offered access to the test and recruited to this study. Intervention: Patients whose GEC was “benign” were offered ultrasound follow-up in lieu of surgery. Those with a “suspicious” GEC were advised to undergo diagnostic lobectomy. Setting: The study was conducted at a large academic medical center. Main Outcome Measure: We measured the rate of benign and suspicious calls from the Afirma GEC and histological diagnosis after surgery. Results: A total of 72 nucleic acid samples were sent for GEC analysis. In 12 (17%) of these samples, there was insufficient mRNA, leaving 60 Afirma results for analysis. Of these, 16 (27%) were benign, whereas 44 (73%) were suspicious. The rate of confirmed malignancy in GEC-suspicious nodules was only 17%. Conclusion: The Afirma GEC demonstrates a lower than expected rate of benign reports in follicular or Hürthle cell neoplasm and a lower than anticipated malignancy rate within GEC-suspicious nodules. These data suggest that the positive predictive value of the GEC is lower than previously reported and call into question the performance of the test when applied in the context of specialized academic cytopathology.
Intensive care unit readmission prevention checklist: is it worth the effort?
O’Horo, John C. , Berrios, Ronaldo A. Sevilla, Whalen, Francis X. , Smischney, Nathan J. , Cawcutt, Kelly , Berrios, Ronaldo Sevilla , O'Horo, John C

Journal of Evaluation in Clinical Practice | April 29, 2014 | Volume: 20 | Issue: 4 | Pages: 348-351

10.1111/jep.12135 | PMID 24779527 Get It

AbstractRationale, aims and objectivesChecklists have been adopted by various institutions to improve patient outcomes. In particular, readmission prevention checklists may be of potential value to improve patient care and reduce medical costs. As a result, a prior quality improvement study was conducted to create an intensive care unit readmission prevention checklist. The previous pilot demonstrated zero readmissions when the readmission prevention checklist was utilized but yielded low compliance (30%). Thus, a subsequent quality initiative was undertaken to refine the readmission prevention checklist with the primary aim of improved compliance while maintaining a reduced readmission rate that was observed with the original quality improvement study.MethodA single‐centre, cross‐sectional study for assessing baseline data and a prospective observational study to assess the effectiveness of a refined readmission prevention checklist tool in a 20‐bed tertiary medical‐surgical intensive care unit at an academic medical centre in Rochester, MN was conducted. Medical patients admitted through the emergency department, upon direct transfer from outside facility, and post‐operative surgical patients at our institution were included. A refined readmission prevention checklist tool was administered during an 8‐week pilot period for medical and post‐operative surgical patients.ResultsThe refined readmission prevention checklist resulted in an even lower compliance (10.5%) from the initial phase likely resulting from utilization of a paper readmission prevention checklist in an electronic medical environment. Moreover, the refined readmission prevention checklist demonstrated a 22% unplanned readmission rate for patients in which the tool was utilized.ConclusionsIn conclusion, the findings of the current quality improvement study may serve to rethink the process of health care delivery that applies paper tools in an electronic medical environment.
Predictors of Chronic Obstructive Pulmonary Disease Exacerbation Reduction in Response to Daily Azithromycin Therapy
Tayob, Nabihah , Murray, Susan , Washko, George R. , Scanlon, Paul D., Casaburi, Richard , Connett, John E. , Lazarus, Stephen C. , Albert, Richard , Woodruff, Prescott G. , Han, MeiLan King , Dransfield, Mark T. , Criner, Gerard J. , Martínez, Fernando J.

American Journal of Respiratory and Critical Care Medicine | April 29, 2014 | Volume: 189 | Issue: 12 | Pages: 1503-1508

10.1164/rccm.201402-0207oc | PMID 24779680 Get It

Abstract Rationale Daily azithromycin decreases acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but long-term side effects are unknown. Objectives To identify the types of exacerbations most likely to be reduced and clinical subgroups most likely to benefit from azithromycin, 250 mg daily, added to usual care. Methods Enrollment criteria included irreversible airflow limitation and AECOPD requiring corticosteroids, emergency department visit, or hospitalization in the prior year or use of supplemental oxygen. Recurrent events and cumulative incidence analyses compared treatment received for AECOPD by randomization group, stratified by subgroups of interest. Cox proportional hazards models estimated treatment effects in subgroups adjusted for age, sex, smoking status, FEV1% predicted, concomitant COPD medications, and oxygen use. Measurements and Main Results Azithromycin was most effective in reducing AECOPD requiring both antibiotic and steroid treatment (n = 1,113; cumulative incidence analysis, P = 0.0002; recurrent events analysis, P = 0.002). No difference in treatment response by sex (P = 0.75), presence of chronic bronchitis (P = 0.19), concomitant inhaled therapy (P = 0.29), or supplemental oxygen use (P = 0.23) was observed. Older age and milder Global Initiative for Chronic Obstructive Lung Disease stage were associated with better treatment response (P = 0.02 and 0.04, respectively). A significant interaction between treatment and current smoking was seen (P = 0.03) and azithromycin did not reduce exacerbations in current smokers (hazard ratio, 0.99; 95% confidence interval, 0.71–1.38; P = 0.95). Conclusions Azithromycin is most effective in preventing AECOPD requiring both antibiotic and steroid treatment. Adjusting for confounders, we saw no difference in efficacy by sex, history of chronic bronchitis, oxygen use, or concomitant COPD therapy. Greater efficacy was seen in older patients and milder Global Initiative for Chronic Obstructive Lung Disease stages. We found little evidence of treatment effect among current smokers. Clinical trial registered with www.clinicaltrials.gov (NCT0011986 and NCT00325897).
Primary pulmonary classical Hodgkin lymphoma: A case report
Schild, Michael H. , Wong, William W. , Valdez, Riccardo, Leis, José F.

Journal of Surgical Oncology | April 29, 2014 | Volume: 110 | Issue: 3 | Pages: 341-344

10.1002/jso.23624 | PMID 24777934 Get It

Primary pulmonary Hodgkin lymphoma (PPHL) is a rare entity. Most reported cases occurred before the availability of PET scan for accurate staging of the disease. We report a case of PPHL for which PET/CT scan was used and surgery was performed to confirm the diagnosis. A review of cases of PPHL since 1990 suggests that adjuvant chemotherapy and/or radiation therapy after surgical resection of the lung lesions achieve better disease control than surgical resection alone. J. Surg. Oncol. 2014 110:341–344. © 2014 Wiley Periodicals, Inc.
Imaging Features of AlloDerm®Used in Postmastectomy Breast Reconstructions
Lee, Christine U. , Clapp, Allison J., Jacobson, Steven R.

Journal of Clinical Imaging Science | April 29, 2014 | Volume: 4 | Issue: No issue available | Pages: 19

10.4103/2156-7514.131641 | PMID 24987566 Get It

The purpose of this pictorial essay is to demonstrate the imaging features (ultrasound, mammogram, and magnetic resonance imaging (MRI)) of AlloDerm®(LifeCell Corp.; Branchburg, NJ), an acellular dermal matrix sometimes used in both primary and reconstructive breast surgeries. AlloDerm®is derived from cadaveric dermis and provides an immunologically inert scaffold in tissue reconstruction. Since there is little literature on the imaging of this substance, radiologists may be unfamiliar with its appearance in breast imaging. For this manuscript,ex vivoandin vivoimages of AlloDerm®in postmastectomy patients were evaluated using different imaging modalities. The appearance of AlloDerm®can vary based on length of time postsurgery and incorporation into the host. AlloDerm®appears as an isodense to glandular tissue on a mammogram and isoechoic to glandular tissue on ultrasound imaging. On MRI, in comparison with normal breast parenchyma, AlloDerm®is hyperintense on T2-weighted imaging and isointense on T1-weighted imaging and demonstrates mild enhancement. To the best of the authors’ knowledge, this is the first multimodality imaging description of AlloDerm®used in postmastectomy patients. The conformation of AlloDerm®at surgical placement and the degree of host cell migration and neoangiogenesis are factors to take into consideration when performing diagnostic evaluations; and, familiarity with the various imaging appearances of AlloDerm®can be helpful to exclude residual or recurrent disease.
Long-term Benefits of an Early Online Problem-Solving Intervention for Executive Dysfunction After Traumatic Brain Injury in Children
Kurowski, Brad G. , Wade, Shari L. , Kirkwood, Michael W. , Brown, Tanya M. , Stancin, Terry , Taylor, Hudson Gerry

JAMA Pediatrics | April 28, 2014 | Volume: 168 | Issue: 6 | Pages: 523

10.1001/jamapediatrics.2013.5070 | PMID 24781374 Get It

Emerging β-Amyloid Pathology and Accelerated Cortical Atrophy
Mattsson, Niklas , Nosheny, Rachel L. , Tosun, Duygu , Trojanowski, John Q. , Shaw, Leslie M. , Donohue, Michael , Weiner, Michael W. , Insel, Philip S. , Jack, Clifford R. , Donohue, Michael C , Tosun, Duygu

JAMA Neurology | April 28, 2014 | Volume: 71 | Issue: 6 | Pages: 725

10.1001/jamaneurol.2014.446 | PMID 24781145 Get It